Want to see HK:6669 full AI Analyst Report?
Top Page
Acotec Scientific Holdings Limited
(6669)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$8.00
▼(-43.50% Downside)
Action:Reiterated
Date:04/29/26
The score is mainly supported by improving financial performance (better margins, modest leverage, and stronger cash conversion in 2025). Offsetting this, technical signals are clearly weak with the price below major moving averages and negative MACD, and valuation looks only fair-to-expensive on a ~31.5 P/E without a dividend yield indicated.
Positive Factors
High Gross Margins
Sustained gross margin near 72% indicates strong product-level economics and likely pricing power or favorable mix in interventional devices. That level of structural margin supports durable profitability and reinvestment capacity even if procedure volumes ebb, improving long-term business resilience.
Negative Factors
Historic Volatility & Past Losses
The company’s earlier losses and a period of negative equity highlight execution risk and cyclicality in its business model. This history indicates the firm can be sensitive to market or product adoption setbacks, so consistency of profit generation remains an open structural risk.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margin near 72% indicates strong product-level economics and likely pricing power or favorable mix in interventional devices. That level of structural margin supports durable profitability and reinvestment capacity even if procedure volumes ebb, improving long-term business resilience.
Read all positive factors
Acotec Scientific Holdings Limited (6669) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.42B
Dividend YieldN/A
Average Volume (3M)462.19K
Price to Earnings (P/E)17.9
Beta (1Y)1.09
Revenue Growth20.65%
EPS Growth127.07%
CountryHK
Employees650
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.34
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.51
Price to Sales (P/S)5.75
P/FCF Ratio25.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.00Price Target Upside20.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$732.25M
Acotec Scientific Holdings Limited Business Overview & Revenue Model
Company Description
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various ...
How the Company Makes Money
Acotec Scientific primarily makes money by selling interventional medical devices to healthcare providers (typically hospitals) for use in clinical procedures. Revenue is generated from (1) product sales across its interventional device portfolio,...
Acotec Scientific Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 592.85M | 644.63M | 533.99M | 473.85M | 395.55M | 303.81M |
| Gross Profit | 446.01M | 476.31M | 402.72M | 377.42M | 336.35M | 265.94M |
| EBITDA | 81.08M | 129.65M | 112.48M | 70.54M | 91.17M | -51.02M |
| Net Income | 100.90M | 119.18M | 52.28M | 14.49M | 70.14M | -79.08M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.87B | 1.66B | 1.61B | 1.41B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 995.38M | 948.37M | 809.57M | 879.21M | 986.46M | 1.14B |
| Total Debt | 236.13M | 244.49M | 202.92M | 234.00M | 47.78M | 24.57M |
| Total Liabilities | 384.00M | 392.18M | 312.76M | 314.53M | 134.46M | 100.17M |
| Stockholders Equity | 1.44B | 1.48B | 1.35B | 1.30B | 1.28B | 1.21B |
Cash Flow | ||||||
| Free Cash Flow | 159.00M | 145.46M | 5.31M | -92.54M | -115.45M | -31.72M |
| Operating Cash Flow | 194.51M | 167.32M | 102.79M | -12.88M | -68.75M | -10.48M |
| Investing Cash Flow | -203.20M | -527.16M | 45.02M | -319.22M | -49.17M | -20.48M |
| Financing Cash Flow | -35.32M | 24.79M | -35.24M | -23.21M | -32.87M | 1.02B |
Acotec Scientific Holdings Limited Technical Analysis
Negative
14.16
Price Trends
9.24
Negative
11.01
Negative
12.07
Negative
Market Momentum
-0.39
Positive
32.24
Neutral
13.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Negative. The current price of 14.16 is above the 20-day moving average (MA) of 8.40, above the 50-day MA of 9.24, and above the 200-day MA of 12.07, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 32.24 is Neutral, neither overbought nor oversold. The STOCH value of 13.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6669.
Acotec Scientific Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$5.57B | 14.99 | 12.01% | 1.26% | 10.19% | 23.70% | |
65 Neutral | HK$6.35B | 29.50 | 10.38% | 1.50% | 3.83% | -27.04% | |
61 Neutral | HK$5.92B | 37.29 | 4.06% | ― | 5.10% | -32.48% | |
59 Neutral | HK$2.42B | 17.87 | 7.22% | ― | 20.65% | 127.07% | |
59 Neutral | HK$2.97B | 57.50 | 2.07% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$11.33B | 33.32 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
HK:6669
Acotec Scientific Holdings Limited
8.28
-0.52
-5.91%
HK:0853
MicroPort Scientific
6.48
-2.28
-26.03%
HK:1302
LifeTech Scientific Corporation
1.42
-0.61
-30.05%
HK:1789
AK Medical Holdings Ltd.
5.19
-0.67
-11.36%
HK:2172
MicroPort NeuroTech Limited
10.92
-1.90
-14.82%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.12
1.20
20.27%
Acotec Scientific Holdings Limited Corporate Events
Acotec Shareholders Approve All Resolutions at 2026 AGM
Jun 16, 2026
Acotec Scientific Holdings Limited reported that all resolutions proposed at its annual general meeting held in Beijing on June 16, 2026, were approved by shareholders via poll. Shareholders adopted the audited financial statements for the year en...
Acotec Scientific Sets June 2026 AGM to Approve Accounts, Board and Share Issuance Mandate
May 22, 2026
Acotec Scientific Holdings Limited has called its annual general meeting for June 16, 2026 in Beijing, where shareholders will review the audited consolidated financial statements for the year ended December 31, 2025 and the accompanying reports o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.